Shandong Sinobioway Biomedicine Co., Ltd. (002581) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shandong Sinobioway Biomedicine Co., Ltd.

Why is Shandong Sinobioway Biomedicine Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of -4.56% and Operating profit at -5.97% over the last 5 years

Negative results in Sep 25

NET SALES(HY) At CNY 175.53 MM has Grown at -23.98%
NET PROFIT(HY) At CNY -31.96 MM has Grown at -175.5%
OPERATING CASH FLOW(Y) Lowest at CNY -53.82 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -25.23%, its profits have risen by 30.4%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -25.23% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shandong Sinobioway Biomedicine Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shandong Sinobioway Biomedicine Co., Ltd.

-23.79%

-0.65

48.35%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.56%

EBIT Growth (5y)

-5.97%

EBIT to Interest (avg)

-31.32

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.23

Sales to Capital Employed (avg)

0.17

Tax Ratio

13.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

2.48%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.86

EV to EBIT

-19.32

EV to EBITDA

-22.83

EV to Capital Employed

3.46

EV to Sales

22.74

PEG Ratio

Dividend Yield

ROCE (Latest)

-17.93%

ROE (Latest)

-11.06%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

NET SALES(Q)

Highest at CNY 141.28 MM

PRE-TAX PROFIT(Q)

At CNY -7.76 MM has Grown at 88.98%

NET PROFIT(Q)

At CNY -1.51 MM has Grown at 96.55%

-23What is not working for the Company

NET SALES(HY)

At CNY 175.53 MM has Grown at -23.98%

NET PROFIT(HY)

At CNY -31.96 MM has Grown at -175.5%

OPERATING CASH FLOW(Y)

Lowest at CNY -53.82 MM

RAW MATERIAL COST(Y)

Grown by 72.07% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 1 times

Here's what is working for Shandong Sinobioway Biomedicine Co., Ltd.

Net Sales

At CNY 141.28 MM has Grown at 159.51%

over average net sales of the previous four periods of CNY 54.44 MM

MOJO Watch

Near term sales trend is extremely positive

Net Sales (CNY MM)

Net Sales

Highest at CNY 141.28 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

At CNY -7.76 MM has Grown at 88.98%

over average net sales of the previous four periods of CNY -70.44 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -1.51 MM has Grown at 96.55%

over average net sales of the previous four periods of CNY -43.75 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Here's what is not working for Shandong Sinobioway Biomedicine Co., Ltd.

Operating Cash Flow

Lowest at CNY -53.82 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debtors Turnover Ratio

Lowest at 1 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 72.07% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales